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Detection and identification of methyl mercapto
hydroxypurine, a major metabolite of
mercaptopurine in plasma during intravenous
administration
G a r i n  W. K e u z e n k a m p - J a n s e n , 1,2* J o h n  M. v a n  B a a l , 1,2 R o n n e y  A . D e  A b r e u , 1,2
J a n  G.N. d e  J o n g , 2 R i c h a r d  Z u i d e r e n t  2 and J.M. F r a n s  T r i j b e l s 2
■Mercaptopurine, a hypoxanthine antimetabolite, is us 
the treatment of acute lymphoblastic leukemia (ALL)
6-Mercaptopurine (6MP) is a hypoxanthine antimetabolite used 
in the treatment of acute lymphoblastic leukemia (ALL)/ It has
metabolized before it exerts cytotoxic no intrinsic cytotoxic activity, but is converted into active
■mercapto-2,8-dihydroxypu
methylmer
roxypunne
viously reported in plasma. This compound was found in 
high concentrations in plasma during high-dose 6-mercap- 
topurine infusions (1300 mg/m2 in 24 h). This previously 
unknown compound was identified by reversed-phase 
HPLC with absorbance detection and by gas chromatog­
raphy-mass spectrometry. The pathways leading to 
6 - in e thy 1 m er cap t o - 8 - hy d r o xy pu ii n e in vivo are not yet fully 
understood. In a group of 17 patients treated widi four 
courses of high-dose 6-mercaptopurine infusions according 
to the ALL-8 treatment protocol of the Dutch Childhood 
Leukemia Study Group, the steady-state concentrations of 
6-methylmercapto-8-hydroxypurinc in plasma were one-
of the parent drug concentrations, with wide interin- 
dividual variation. The formation of high concentrations of 
6-methylmercapto-8-hydroxypurine in plasma, especially
metabolites before it exerts its cytotoxic action. The first step in
W e the anabolic padiway of 6MP is its conversion into the nucle-
otide, thioinosine monophosphate (Fig. 1). This compound is 
converted into thioguanosine monophosphate, which is cyto­
toxic after incorporation into DNA and RNA ///, or into 
methylthioinosine monophosphate, which is an inhibitor of the 
purine de novo synthesis [2j. 6MP can be methylated into
6-methyhnercaptopurine (6MeMP). 6MeMP ri
(6MeMPR) is the product of the breakdown of methylthio- 
itiosme monophosphate or of the méthylation of 6MP riboside. 
Xanthine oxidase (EG 1.2.3.2), which is mainly active in the liver 
and kidney [3], catabolizes 6MP into thiouric acid (6-mercapto- 
2,8-dihydroxypurine). This oxidation occurs via 6-mercapto-H- 
hydroxypurine (6MBOHP) and to a lesser extent via thioxan- 
thine (6-mercapto-2-hydroxypurine) [4]. Previous j 
humans demonstrated that 6MP and thiouric acid are the major 
compounds, and thioxanthine and 6MP riboside the minor ones, 
that are excreted in urine during 6MP administration ¡S-IOj, 
indicating that degradation of 6MP occurs mainly via xanthine 
oxidase. Another pathway leading to the inactivation of 6MP in
in
during the infusion, probably indicates another catabolic humans is desulfuradon of the drug, which probably occurs via 
pathway of high-dose 6-mercaptopurine, apart from its mcthylthiopurines [7J.
conversion into thiouric acid. When treating patients with high-dose 6MP infusions, we
found considerable amounts of a hitherto unknown compound 
INDEXING TERMS: acute lymphoblastic leukemia • methotrexate in plasma [11]. After purification, the compound was identified 
• drug metabolism • thiouric acid by H PLC and gas chromatography-mass spectrometry (GC-
MS) as 6-methylmercapto-8-hydroxypurine (6MeM8QlIP).
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6-7  with Iv,lIP( V  The metabolites were separated by re- 
verscd-phase H PLC  with a 250 X  4.6 mm (i.d.) column of 
Supelcosil LC-18-DB (particle size 5 /u,m; Supelco, Bellefonte, 
PA). The mobile phase (flow rate 1.25 mL/min) consisted of a 
gradient from 0 to 25 min of two buffers, starting with 98:2 (by 
vol) buffer A (25 nmiol/L KILPO..) and buffer B (3 volumes of 
50 mmol/L IvI I_»P04 plus 1 volume of methanol) and changing 
to 20:80 buffer A:buffer B; the latter conditions were maintained
injection. Elating analytes were
detected with a variable ultraviolet-visible absorbance detector
(Spectra Focus 2000 11R system; Thermo Separation Products, 
Fremont, CA). For routine measurement the wavelengths were 
set at 290 and 320 ntn; occasionally, the spectra of the peaks 
were scanned between 250 and 350 nm (III.
6M-2-OHP
2
0M-2.8-OHP
2
6M-8-OHP
1
I
»  6M«M-8-OHP
Fig. 1. Metabolism of 6MP.
(TGN) thioguanine nucleotides, (PDNS) purine de novo synthesis, (tGMP) 6-thi0- 
guanosine monophosphate, (tIMP) 6-thiolnosine monophosphate, (MetiMP) 
6-methyithloinosine monophosphate.For all other metabolites: Me = methyl, M 
= mercapto, OH = hydroxy, P = purine. (1) Thlopurine methyltransferase (EC 
2.1.1.67), (2) xanthine oxidase (EC 1.2.3.2). The dotted lines represent path­
ways not definitely established.
The presence of this metabolite of 6MP in plasma has not been 
described before and may point to another catabolic pathway of 
high-dose 6MP.
Patients and Methods
PATIENTS
Patients with ALL (n =  17) were treated in our center according 
to the treatment' protocol of the Dutch Childhood Leukemia 
Study Group (ALL 8 Study). They received four courses with
high-dose methotrexate infusion (5 g • m ~ in 24 h, from 0 to 24
GC'-MS.'Vhc unknown com 
X I 'Ft) form the tri
was c from plasma by
silyl (TMS) derivative, we 
the isolated and lyophilized material in 50 /xL of an
tr
ivolume mixture of
roaceti
and JV, 0 -bis(tri
10 rnL/L trim ane
(Pierce, Rockford, IL). We carried out the derivatization at 
60 °C for 30 min, after which we diluted the mixture with 50 ¡iL 
of chloroform. The 6MeMBOHP calibrator was trimethylsily- 
lated by the same procedure and used as a reference. To separate 
the products, we used a HP5890 gas chromatograph (Hewlett- 
Packard, Amsterdam, The Netherlands), using a 25 m X 0.32 
mm (i.d.) CP-sil-8CB column with a film thickness of 0.12 ¡xm 
(Chrompack, Middelburg, 'The Netherlands) and split injection. 
The carrier gas was helium at a column head pressure of 48.3 
kPa. The oven temperature was programmed from 70 °C to
280 °C.
The metabolite of 6MP was identified with a VG-trio-2 
quadrupole mass spectrometer (Fisons Instruments, Cheshire, 
UK) in electron impact ionization mode at 70 eV and a source 
temperature of 200 °C. Scan measurements were performed 
from 40 to 650 amu with a scan time of 1 s and an intersean delay
h) followed immediately by a high-dose 6MP infusion (1300 of 0.1 s. Selected ion recording measurements were performed
r • m in 24 h, from 24 to 48 h). Plasma was sampled before 
at 24, 28, 42, 48, 52, and 72 h after the start: of the
a t ; specific ions 2:<?4. 1 FFMS) and 326 ( M \  di-TMS
derivative) by using a span of 0.4 amu, a dwell time of 0.08 s, and
methotrexate infusion. Informed consent was obtained from the an interchannel delay of 0,02 s. 
patients or their parents according to the guideline! 
ethical committee of our hospital.
s o f the
STAT IST ICS
MATERIALS
CJ
a tors of 6MP, 6-MP r i , 
ine, and methylthioxanthine were obtained from Sigma 
ical ( '0., St. Louis, MO. Thiouric acid and methylthiouric 
were synthesized as described [11]. 6M 8OHP, 
6MeMBOHP, and 6-methylsulfinyl-8-hydroxypurine were pro­
vided by Gertrude B. Elion, Wellcome Research Labs., Re­
search Triangle Park, NC.
PROCEDURES
IIPLC. HPLC was carried out as described [l lj. In short, plasma 
was extracted with perchloric acid on ice and neutralized to pH
Statistics for 6MP and 6M 0M 8OHP plasma concentrations 
were performed with the :ware '•’f'cati'e for the Social
Sciences f; e statistics at each time point were 
calculated for each course of treatment. A paired /-test (95%
con interval)
compare the conce
each time )
•mg successive courses.
When the paired f-tests did not reach significance (P <0.05), 
concentrations of 6MP and 6M eM 80H P reached during suc­
cessive courses were not significantly different. We also calcu­
lated the individual means of the lour courses for each patient; at
we calculatedeach time point, from 
statistics for the four courses to
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Fig. 2. Chromatograms at 290 nm of plasma sam­
pled at 42 h after start of a methotrexate infusion of 
a patient treated with 24 h of high-dose methotrex­
ate followed by 24 h of high-dose 6MP; 1.8 /xmol/L 
6MeM8GHP was then added to the plasma sample,
(/\) Mobile phase as described in Patients and Methods, 
with the unknown compound and 6MeM80HP eluting at 
29.4 min and 6MeMP at 31 min. (B) Mobile phase as 
described in Resultst with the unknown compound and 
6MeM80HP eluting at 24 min.
Results
On the basis of their retention time and ultraviolet absorbance, 
we determined that none of th
•eover, the ; :e spectra of the unknown compound
e c in
and of 6M eM 80H P were identical (Fig. 3). 
The derivati zed form of the 6M eM 80H P :ator ;
account for the unknown peak. In IIPLC, the a peak with a retention time o f 22.8 min by GC, the mass
com
:rore
in plasma e at 29 min, i.e., 1.5 min
r. 1 we
plasma, the peak6MeM80ITP
compound at 290 nm increased (Fig. 2A). In a
1.8
uni
spectrum of which showed an abundant molecular ion at mh 
326 (M 1) and specific ions at m /z 311 (loss of CPI,), '»>/' «W
(loss of TMS), and m/z 239 (loss of TMS and C H ;1). The
chromatogram of the isolated and derivatized unknown com-
phase, starting with 75:25 (by vol) buffer A:.B and changing to pound showed a peak with a retention time of 23.0 min by GC
25:75 (by vol) cr A:buffer B at 25 min, the unknown with a mass identical to that of the derivatized
compound eluted at 24 min, as did 6M eM 8()IlP  (Fig. 2B). 6MeM8QHP calibrator (Fig. 4, top panels). Selected-ion re
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Fig. 3. Absorbance spectrum at 250-350 nm (top) and scan at the maximum at 29 min (bottom) of the unidentified e 
of 6MeM80HP (B).
in plasma (A) <iru)
cording measurements at the masses m /z  326 and 254 for both pairs). The minimum, median, and maximum concentrations of 
compounds showed retention times of 22.8 and 23.0 min for the 6MP and óMeMHOlIP in 17 patients during the lour treatment
derivad/,ed calibrator and the derivatized unknown compound, 
respectively. The ratio between the ions was comparable (0.12
courses are m Fitr. 5. The concentrations
were i
and 0.19, respectively) (Fig. 4, lower pairs of panels).
* areas peak of the unknown compound in
>f those oi the parent drug. 
Fhe median interindividual (IV during the 6MP infusion was
HIP and 2B% (range
patients1 samples were registered from the chromatograms at 
290 nm, the wavelength at which 6MeMP and 6MeMPR were 
measured. 'Fhe concentrations of the unknown compound were 
then calculated in retrospect. When the unknown e<
39 %
1- 132%)
ne
6-118%)
was not detectable in urine ' . . .  I . J ;  . I _
sion nor in the next 24 h.
was wi, we mi
e
calibration curves at 290 nm for This study provides strong evidence for the presence of 
1.5 min after 6MeMHOHP, and 6MeMKOI llJ in plasma during and after high-dose riiVIP infu­
sions. M'he mass spectra of rtMeJVIHOHP anti of 6-mt:IP. 'Fhe correl
6M eM 80H P (y) and 6MeMP (a?) yielded the equation y  ~  
0.9468a* + 68.9 nmol/L. The concentrations' of the unknown 
compound were first calculated from the areas of the unknown 
compound at 290 nm and the calibration curves of 6MeMP at 
290 nm, which we had available from all series o f FIPLC 
measurements. These results (Rl) were corrected for the differ-
the two calibration curves: 6MeM8C)lIP coneen-
xanthine (6-methylniercapto-2-hydroxypurine) might be idemi
FIPLC excluded 
was 6-me
that mown
IOXÏ
<
ne, showing a retention time 
>f 18.7 min for the latter compound and different absorbance 
spectra.
T o our knowledge, the presence of 6MeM8C)l IP in plasma 
has not been described before. A metabolite o f  6.\lc.\lP  de*
t r a t io n 0.9468 + 68.9 nmol/L.
no signifie
ser in urine of one patient accounted for 0.5% oí
enees in concentrations of excretion of orally :
6MP or 6MeM80TIP reached during the successive courses at 6MeM8QHP. In our study, plasma 6Mt
was proliablv
concentra
28, 48, 52, or 72 h (P  =  0 .159-0.994, paired f-tests, 15-17 tions were ; of : parent drug concentrations,
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Fig. 4. (Upper pair of panels) Mass spectra of the 
6MeM80HP calibrator and the unknown compound; (lower 
pairs of panels) selected-ion recording (SIR) measurements 
of the 6MeM80HP calibrator and the unknown compound.
both of which displayed wide interindividual variation. For -window phase with one high-dose 6MP infusion and with the 
6M eM 80HP, part of this variation may be caused by the wide xanthine oxidase inhibitor allopurinol [14 ,15]  contained a peak
at 320 urn with the same retention time as 6M 8OHP, i.e., 1 mill 
± 6 s before the peak of 6MP. This peak was present during and 
after the 6MP infusion, and the area under the peak was
variation in thiopurine
(TPMT; EC 2.1.1.67) activity. T P M T  shows a genetic poly­
morphism, with 88.6% of the subjects demonstrating high
activity and 11.1% intermediate activity. About 1 in 300 subjects 20-31% of that of 6MP in one patient (6MP steady-state 57 
has undetectable T P M T  activity [12[. /¿mol/L) [14] and 6-11%  in the other (6MP steady-state 35
placenta) [13]
ow r  is
TPM T activity is highest in liver and kidney but has been /xrnol/L) [15]. W e received the 6M 80I1P calibrator only re-
detected in all other tissues examined (erythrocytes, lympho- cently from Dr. Elion. However, no more plasma from these
s, thrombocytes, lymphoblasts, lung, intestine, brain, and two patients is available for analysis, so we cannot confirm that
this peak was actually 6M 8OHP. The presence of this peak in
formed in vivo is not known. Two the chromatograms of plasma of two patients with high 6MP
metabolic routes may lead to the formation of this compound: steady-state concentrations and allopurinol treatment— and the
inethylation of 6 M 8 0 H P  or 8-oxidation of 6MeMP. Evidences absence of it in all chromatograms of the 17 patients treated with
exist from in vitro studies that oxidation of 6MP by xanthine high-dose 6MP without allopurinol—suggest that 6M 80I1P
oxidase preferentially occurs first at the 8 position and then at can be produced in vivo and is rapidly further oxidized by 
position 2, in contrast to hypoxanthine, which is first oxidized on
C-2 and subsequently on C-8 [4[. 6MBOHP has not been 
described in vivo, which may be explained by a higher activity of 
xanthine oxidase towards 6M 8QHP than towards 6MP [4]. W e  
did not find 6 M 8 0 H P  in plasma or urine of the 17 patients.
However, plasma of two patients treated in a
xanthine oxidase into thiouric acid.
Recently, Deininger et al. demonstrated a VWiXJ K m ratio o f
16.9 for T P M T  with 6 M 8 0 H P  as substrate (K ,,, 96.1 "h Zm t *  A m  •
), whereas that with 6MP substrate was only 2.34 (Km
ju-mol/L), indicating that 6M 80H P  is a
•ate than 6MP for T P M T  [16]. Thus, 6McM8C)HP might
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oxidation of 6M 80H P , or the involvement of xanthine oxidase 
in any further ism
The absence of 6M eM 80IIP in urine of our patients might
he by glucuronidation or ation into
6-methylthiouric acid or 6-methylsulfinyl-8-hydroxypurine. 
6M eM 8()HP glucuronide accounted for 12-20% of the admin­
istered 6MeMP dose in urine ¡6], In urine of two patients treated 
either orally or intravenously with 6-rS5ylA/rn cons
0 24 48 72
h
amounts of 6-inethyl-f S|sulFmyI-8-hydroxypurine and some 
,sS]sulfate were excreted j l j .  In a patient treated with 6-meth- 
yl-| <sS]MP, 36% of the administered dose was excreted in urine 
as 6-methyl-f'v\SJsulfiny.1-8-hydroxypurine and 27% as radioac­
tive sulfate [6J. In humans, désulfuration of the thiopurine with 
formation of inorganic sulfate appears to occur via the methyl-
a larger amount of sulfate than theHinnes,
thiopurines do [7], Because désulfuration of
Fig. 5. Minimum, median, and maximum plasma concentrations of by allopurinol [IS], xanthine oxid
is not <
is not mv< m
6MeM80HP (— ) and 6MP (---) during four courses with high-dose 
methotrexate infusions (5 g • m 2 in 24 h) immediately followed by 
high-dose 6MP infusions (1300 mg ■ m 2 in 24 h) in 17 patients.
be produced by méthylation o f 6M 80H P . On the other hand,
6MeM80HP might also be pr by oxidation of 6MeMP.
In vitro studies have si:own that the relative oxidation rate of 
6MeMP (relative to that of purine) was 15% for aldehyde
ciciase (aldehyderoxygen oxidoreduetase purified from rabbit 
liver, EC 1.2.3.1) and <3% for xanthine oxidase (xanthine: 
oxygen oxidoreduetase purified from bovine milk, EC 1.2.3.2)
[171. In our experience, xanthine oxidase (xanthine:oxygen oxi­
doreduetase from buttermilk, EC 1.1.3.22; Sigma) converted
onlv "■ 10% of 6MeMP into 6M eM 80H P  in 4 h. Studies
showing that thiouric acid is the main cala boi ile of 6MP in vivo
I) - S\ 10j, and in vitro data stradng that oxidation of 6MP
occurs preferentially first on G-8 ¡4} and that the ratio
6M 8OI IP as substrate than with 6MPfor I r ta »1 IS rner
¡16], suggest that 6M eM 8()lIP  may well be produced by 
methylation of 6M8QHP. Enzyme kinetic studies of xanthine 
oxidase and aldehyde oxidase (which is mainly active in the liver) 
with (methyl)thiopurine substrates are needed to elucidate the 
pathway leading to 6MeM8( )I IP. (iiven the wide interindi-
vtclvial variation o f T P M T //2 / ,  it is important to know whether 
this enzymes acts to methylate 6A'18()I IP, which is a catabolito 
of 6MP, or 6MP, which is available for the anabolic pathway
• ♦>■ to cytotoxicity.
We treated nine patients with non-Hodgkin lymphoma at 
diagnosis with one high-dose 6MP infusion within a therapeutic 
window. Four patients received oral allopurinol and five did not. 
Plasma concentrations o f  6MP, thioxan thine, and 6Me/VIP were 
higher and those of thiouric acid lower in the allopurinol-treated 
patients than in those who did not receive allopurinol [IS].  The  
present study shows that 
higher in the group treated with allopurinol (3.7-17 /xmol/L) 
than in those with no allopurinol (1.1-2.9 jumol/L). The higher 
concentrations of 6MeiVI8C)I IP in the allopurinol group may he
concentrations were
¿•her concentrations of
•  I
111
this group / / 5y, the allopurinol-induced inhibition of further
uration of uopunnes.
In conclusion, the present study shows that 6MeM8QHP is a 
major metabolite of 6MP in plasma during high-dose 6MP 
infusions, whereas smaller amounts of 6MeMP, 6MeMPR, and 
thioxanthine are produced in plasma [19]. The metabolic path­
way leading to the formation of 6MeM80HP or the further 
metabolism of this catabolite is not completely solved. Measure­
ment of the 8-hydroxylated metabolites of 6MP in plasma and 
urine during high-dose 6MP infusions, as w'ell as enzyme kinetic 
studies for xanthine oxidase and aldehyde oxidase 
yI)thiopurine substrates, must he performed before we can 
obtain better insight into the catabolism of 6MP (apart from its 
conversion into thiouric acid) and the role of T P M T  in
W e acknowledge the assistance o f  G.B. Elion for providing the 
8-hydroxvlated calibrators of 6MP and for
* W
regarding the metabolic pathways of 6MeM8()MP. This study 
was supported by a grant o f the Dutch Cancer Society/
0 1 
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